Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;158(3):531-537.
doi: 10.1016/j.ygyno.2020.06.499. Epub 2020 Jul 5.

Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations

Katherine C Kurnit  1 , Pankti Reid  2 , John W Moroney  3 , Gini F Fleming  4
Affiliations
Review

Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations

Katherine C Kurnit et al. Gynecol Oncol. 2020 Sep.

Abstract

Immune checkpoint inhibitors are an exciting new class of cancer therapeutics. Recently, a PD-1 inhibitor has been approved by the Food and Drug Administration for several indications that are relevant to patients with gynecologic malignancies. In this review, we explore the clinical considerations for the use of checkpoint inhibitor therapy in this population. Specifically, we will discuss the approved indications, recommended dosing, clinical monitoring while on treatment, common adverse events, and treatment of adverse events should they arise. Additionally, we will review mechanisms of resistance and other challenges associated with the use of checkpoint inhibitors. We will conclude with a discussion of possible future directions for immunotherapy in women with gynecologic cancers.

Keywords: Checkpoint inhibitors; Gynecologic cancers; Immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Disclosures KCK reports travel support from GOG-Foundation, served on an advisory board for GOG-Foundation regarding LEAP Therapeutics, outside the submitted work. GFF reports personal fees from Up To Date, non-financial support from Corcept, personal fees from GSK, personal fees from ASCO, personal fees from Vaniam Group, unpaid membership on clinical trial steering committee from AbbVie, and is an Institutional PI of Industry Trials from Merck, Syndax, 47 Inc., Sanofi, Astex, EMD Sereno, Roche/Genentech, Syros, Tesaro, Iovance, Sanofi, Sermonix, Incyte, Compugen, Abbvie, and Eisai, outside the submitted work. PR and JWM report no disclosures.

MeSH terms

LinkOut - more resources